Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. It has bacteriostatic activity against susceptible organisms.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
600 mg to 900 mg IV every 8 hours, or 900 mg to 1200 mg IV every 12 hours. Maximum 4800 mg/day.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in adults, 2.5-3.5 hours in children, and prolonged to 4-6 hours in severe hepatic impairment; clinically relevant for dosing interval (typically q6-8h).
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Approximately 10-20% renal excretion as active clindamycin and its metabolites; 40-60% biliary/fecal excretion as inactive metabolites; primarily hepatic metabolism with enterohepatic circulation.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte